ArticleFarmaceuticos comunitarios2025
[Phenotypic Classification of Diabetes: A Personalized Approach for Pharmaceutical Practice].
Article in Farmaceuticos comunitarios, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetes mellitus (DM) is a heterogeneous metabolic disease with multiple pathophysiological mechanisms. The traditional classification into type 1 diabetes (T1D) and type 2 diabetes (T2D) does not fully capture the diversity of clinical and metabolic profiles among patients. Recently, Ahlqvist et al. proposed a model based on five phenotypic subtypes, enabling a more precise stratification of the disease and a personalized therapeutic approach. Methods: Through cluster analysis in cohorts of diabetic patients, five subgroups were identified: Severe Autoimmune Diabetes (SAID), Severe Insulin Deficient Diabetes (SIDD), Severe Insulin Resistant Diabetes (SIRD), Mild Obesity-related Diabetes (MOD), and Mild Age-related Diabetes (MARD). These phenotypes differ in pathophysiology, disease progression, and treatment response. Results and Discussion: Phenotypic stratification allows better prediction of microvascular and macrovascular complications, optimizes pharmacotherapy, and enhances personalized interventions. In community pharmacy, this classification could improve subtype identification, facilitate more precise therapeutic recommendations, and promote treatment adherence. However, its implementation faces challenges, such as limited access to key biomarkers. Conclusions: The phenotypic classification of DM represents a step toward personalized medicine. As key healthcare professionals in chronic disease management, community pharmacists can play a crucial role in its application, improving patient education and therapeutic monitoring to enhance clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.